FIELD: biotechnologies.
SUBSTANCE: invention relates to the biotechnology. Disclosed is a mitochondria imported RNA with subdomains of transport RNA lysine HD and HF. Each of the presented RNA guides (gRNA-HF-HF, gRNA-HF-HD, gRNA-HD-HF and gRNA-HD-HD) interacts with human mitochondrial tRNA-lysyl synthase (pre-KARS2) and ENO2 protein, which are imported into mitochondria together with RNA guide. In the mitochondria, the RNA guide binds to SpCas9 nuclease, forming a functional complex which introduces double-strand breaks in mtDNA, which lead to its elimination by enzymes of the mitochondrial replication system. Total mtDNA pool in mitochondria is recovered by remaining mtDNA.
EFFECT: providing a system for eliminating certain haplotypes of RGEN/SpCas9 mtDNA and a method for delivering RNA thereof in parts of organelle.
1 cl, 2 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
GENETIC CONSTRUCTS ENCODING NUCLEASES Cas9-BE4-Gam AND Cas9-ABE 7.10, WHICH ARE DIRECTED INTO MITOCHONDRIA OF HUMAN CELLS | 2018 |
|
RU2709739C1 |
GENETIC CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT DEAMINASES BASED ON APOBE1 FOR TARGETED MODIFICATION OF MITOCHONDRIAL DNA CYTOSINE BASES | 2022 |
|
RU2800362C1 |
GENETIC CONSTRUCT BASED ON CRISPR/Cas9 GENOME SYSTEM EDITING, CODING Cas9 NUCLEASE, SPECIFICALLY IMPORTED IN HUMAN CELLS MITOCHONDRIA | 2015 |
|
RU2634395C1 |
GENETIC CONSTRUCT PMITOASCPF1, CODING NUCLEASE ASCPF1 WITH DETERMINANT OF IMPLANTATION IN THE MITOCHONDRIA OF HUMAN CELLS | 2016 |
|
RU2662994C2 |
METHOD FOR CORRECTION OF MITOCHONDRIAL DYSFUNCTION BY GENETIC CONSTRUCT | 2016 |
|
RU2642972C1 |
MODIFIED IMMUNOREGULATORY ELEMENT AND IMMUNITY CHANGE BY THIS ELEMENT | 2017 |
|
RU2767206C2 |
METHOD TO INCREASE EFFECTIVENESS OF DNA PENETRATION IN EUCARIOTIC CELLS MITOCHONDRIA | 2015 |
|
RU2628701C2 |
GENOMIC DNA EDITING SYSTEM OF AN EUKARYOTIC CELL BASED ON THE NUCLEOTIDE SEQUENCE ENCODING THE SUCAS9NLS PROTEIN | 2022 |
|
RU2804422C1 |
CRISPR ENZYME MUTATIONS REDUCING NON-TARGETED EFFECTS | 2016 |
|
RU2752834C2 |
DELIVERY AND USE OF SYSTEMS OF CRISPR-CAS, VECTORS AND COMPOSITIONS FOR TARGETED ACTION AND THERAPY IN LIVER | 2014 |
|
RU2716420C2 |
Authors
Dates
2020-03-27—Published
2018-10-29—Filed